Bioactive compounds by microalgae and potentials for the management of some human disease conditions.

Microalgae biomasses are excellent sources of diverse bioactive compounds such as lipids, polysaccharides, carotenoids, vitamins, phenolics and phycobiliproteins. Large-scale production of these bioactive substances would require microalgae cultivation either in open-culture systems or closed-culture systems. Some of these bioactive compounds (such as polysaccharides, phycobiliproteins and lipids) are produced during their active growth phase. They appear to have antibacterial, antifungal, antiviral, antioxidative, anticancer, neuroprotective and chemo-preventive activities. These properties confer on microalgae the potential for use in the treatment and/or management of several neurologic and cell dysfunction-related disease conditions, including Alzheimer's disease (AD), AIDS and COVID-19, as shown in this review. Although several health benefits have been highlighted, there appears to be a consensus in the literature that the field of microalgae is still fledgling, and more research needs to be carried out to ascertain the mechanisms of action that underpin the effectiveness of microalgal compounds. In this review, two biosynthetic pathways were modeled to help elucidate the mode of action of the bioactive compounds from microalgae and their products. These are carotenoid and phycobilin proteins biosynthetic pathways. The education of the public on the importance of microalgae backed with empirical scientific evidence will go a long way to ensure that the benefits from research investigations are quickly rolled out. The potential application of these microalgae to some human disease conditions was highlighted.

An in silico analysis of acquired antimicrobial resistance genes in Aeromonas plasmids.

Sequences of 105 Aeromonas species plasmids were probed for acquired anti-microbial resistance (AMR) genes using a bioinformatics approach. The plasmids showed no positive linear correlation between size and GC content and up to 55 acquired AMR genes were found in 39 (37%) plasmids after in silico screening for resistance against 15 antibiotic drug classes. Overall, potential multiple antibiotic resistance (p-MAR) index ranged from 0.07 to 0.53. Up to 18 plasmids were predicted to mediate multiple drug resistance (MDR). Plasmids pS121-1a (A. salmonicida), pWCX23_1 (A. hydrophila) and pASP-a58 (A. veronii) harboured 18, 15 and 14 AMR genes respectively. The five most occurring drug classes for which AMR genes were detected were aminoglycosides (27%), followed by beta-lactams (17%), sulphonamides (13%), fluoroquinolones (13%), and phenicols (10%). The most prevalent genes were a sulphonamide resistant gene Sul1, the gene aac (6')-Ib-cr (aminoglycoside 6'-N-acetyl transferase type Ib-cr) resistant to aminoglycosides and the blaKPC-2 gene, which encodes carbapenemase-production. Plasmid acquisition of AMR genes was mainly inter-genus rather than intra-genus. Eighteen plasmids showed template or host genes acquired from Pseudomonas monteilii, Salmonella enterica or Escherichia coli. The most occurring antimicrobial resistance determinants (ARDs) were beta-lactamase, followed by aminoglycosides acetyl-transferases, and then efflux pumps. Screening of new isolates in vitro and in vivo is required to ascertain the level of phenotypic expression of colistin and other acquired AMR genes detected.